Guggenheim Issues Pessimistic Forecast for Jade Biosciences (NASDAQ:JBIO) Stock Price

Jade Biosciences (NASDAQ:JBIO – Get Free Report) had its target price decreased by analysts at Guggenheim from $47.00 to $41.00 in a note issued to investors on Monday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s target price suggests a potential upside of 166.23% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. BTIG Research reiterated a “buy” rating and issued a $77.00 target price on shares of Jade Biosciences in a research report on Tuesday, October 27th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a research note on Tuesday, August 11th. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Wall Street Zen raised shares of Jade Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a research note on Friday, September 11th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

View Our Latest Research Report on JBIO

Jade Biosciences Trading Up 0.4%

Shares of JBIO opened at $15.40 on Monday. Jade Biosciences has a one year low of $11.02 and a one year high of $28.00. The stock has a 50 day moving average price of $15.15 and a 200 day moving average price of $18.14.

Jade Biosciences (NASDAQ:JBIO – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.31. Equities analysts anticipate that Jade Biosciences will post -2.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jade Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bellevue Group AG raised its holdings in shares of Jade Biosciences by 40.4% during the 3rd quarter. Bellevue Group AG now owns 4,293,937 shares of the company’s stock worth $60,330,000 after acquiring an additional 1,235,941 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Jade Biosciences in the first quarter valued at about $43,557,000. Pictet Asset Management Holding SA grew its holdings in shares of Jade Biosciences by 64.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company’s stock valued at $16,944,000 after purchasing an additional 472,204 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Jade Biosciences by 22.0% in the third quarter. Goldman Sachs Group Inc. now owns 896,834 shares of the company’s stock valued at $12,601,000 after purchasing an additional 161,610 shares during the period. Finally, Jump Financial LLC increased its position in Jade Biosciences by 75.3% during the third quarter. Jump Financial LLC now owns 302,812 shares of the company’s stock worth $4,255,000 after purchasing an additional 130,065 shares during the last quarter.

Jade Biosciences Company Profile

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.

See Also

Analyst Recommendations for Jade Biosciences (NASDAQ:JBIO)

Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.